Ourre Visionbring Impactful Ophthalmic Medicines To As Many Patients As Possible As Quickly As Possiblethe Company Is Pursuing Products That Address Unmet Needscan Be Priced For Accessand Still Have Substantial Commercial Potential Revision Therapeuticsincwas Founded In 2018 To Develop Medicines With High Disease Impactand Rapidly Get Those Medicines To Patientsthe Company Prioritizes Areas Of Unmet Or Poorly Met Needs In Ophthalmic Disorders By Repurposing Approved Or Rescuing Shelved Drugs That Could Change Patientslivesrepurposing Or Rescuing Drugs Allows For Faster Development At A Reduced Costour Lead Program Is A Product For Stargardt Diseasea Retinal Degenerative Disease That Often Begins In Childhoodour Candidate Is A Repurposedgrasgenerally Recognized As Safecyclodextrin Delivered Intravitreally That Could Work As A First Line Therapy Or In Combination With Other Products Currently In Developmentit Can Be Developed Fast And Produced At A Relatively Low Costother Targets Include A Repurposed Drug For Dry Eye Diseasea Rescued Therapy For Proliferative Vitreoretinopathyand A Combination Product To Treat Intraocular Pressure
No conferences found for this company.
| Company Name | Revision Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
